On March 30, 2026, Fortress Biotech, Inc. (Nasdaq: FBIO) announced the successful closing of the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its majority-owned subsidiary, Cyprium Therapeutics, Inc., for gross proceeds of $205 million. This transaction is expected to significantly enhance Fortress Biotech's financial flexibility, allowing for further investments in business development and the advancement of its diverse portfolio of pharmaceutical products.

The PRV was issued following the FDA's approval of ZYCUBO® (copper histidinate), a treatment for Menkes disease, which was developed by Cyprium. Fortress Biotech's Chairman, President, and CEO, Dr. Lindsay A. Rosenwald, emphasized the transformative nature of this sale, stating that it validates the company's business model and positions it for future growth. Following the sale, Fortress anticipates receiving over $100 million from Cyprium, which will include potential future dividends and intercompany agreements.

In addition to the PRV sale, Fortress Biotech has achieved three FDA approvals in the past 15 months for its products Emrosi™, UNLOXCYT™, and ZYCUBO®. The company also successfully divested its former subsidiary, Checkpoint Therapeutics, to Sun Pharma, further diversifying its portfolio. Cyprium remains eligible for tiered royalties on net sales of ZYCUBO® and could receive up to approximately $128 million in aggregate sales milestones from its collaboration with Sentynl Therapeutics.

This strategic move not only strengthens Fortress Biotech's financial position but also enhances its operational execution and strategic outlook, paving the way for future growth opportunities in the biopharmaceutical sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.